Javascript must be enabled to continue!
Pre-Transplant Autonomic Nervous System Malfunction Is a Powerful Predictor for Survival after Allogeneic Hematopoietic Cell Transplantation
View through CrossRef
Abstract
Background: Autonomic nerve function can be affected by various factors such as patient activity of daily living, disease status, treatment history and/or comorbidity. Indeed, autonomic nervous system dysfunction, as indexed by heart rate variability (HRV), has shown prognostic value for various disease outcomes, but its influence on outcomes following allogeneic hematopoietic cell transplantation (allo-HCT) is unclear. We therefore conducted a prospective observational study to determine the impact of autonomic nervous system dysfunction on outcomes following allo-HCT.
Methods: From July 2011 to July 2013, we prospectively registered patients who had received allo-HCT in our institute. We also applied well-established examination of HRV as a surrogate maker of the autonomic nervous system. HRV data were collected from 24-hour ambulatory ECG recordings within 28 days of the starting day of the conditioning regimen for allo-HCT. Obtained data were analyzed with RR data analysis software (MemCalc/CHIRAM version 3, GMS Co., LTD., Tokyo, Japan). The following parameters were employed as markers of HRV: standard deviation of NN interval (SDNN) and the squares of the differences between adjacent normal-to-normal RR intervals (r-MSSD) in time domain analysis, and low-frequency (LF) and high-frequency (HF) power in frequency domain analysis. Δ Akaike's information criterion (Δ AIC) was used to compare the HRV components-added model to the basic model by the Pre-transplantation Assessment of Mortality (PAM) score, HCT-specific comorbidity index (HCT-CI), or disease risk index (DRI) in a Cox proportional hazards model.
Results: We registered 112 consecutive allo-HCTs (103 patients) who agreed to participate in this study. The median age of the patients was 45.5 years (range: 18-66) and the median follow-up period for survivors (76 patients) was 961 days (range: 159-1654). Diagnoses included acute myeloid leukemia (n=55, 49%), acute lymphoid leukemia/lymphoblastic lymphoma (n=13, 12%), mixed phenotype acute leukemia (n=3, 3%), myelodysplastic syndrome (n=15, 13%), adult T cell leukemia/lymphoma (n=7, 6%), aggressive lymphomas (n=6, 5%), indolent lymphoma/chronic lymphoid leukemia (n=3, 3%), chronic myeloid leukemia/other myeloproliferative neoplasms (n=5, 4%), aplastic anemia (n=2, 2%), and others (n=3, 3%). Stem cell sources consisted of HLA-matched related donors for 18 transplants (16%), mismatched related donors for 24 transplants (22%), matched unrelated donors for 32 transplants (29%), mismatched unrelated donors for 8 transplants (7%), and cord blood for 30 transplants (27%). Myeloablative conditioning was employed for 84 transplants (75%).
Median value of LF, HF, SDNN, and r-MSSD was 409 msec2 (range: 27-1279), 103 msec2 (range: 5-1309), 122 msec (range: 48-231), and 20 msec (range: 4-95), respectively.From univariate analysis, the reduction of LF, HF, SDNN, or r-MSSD was significantly associated with decreased probability of OS (hazard ratio (HR): 0.7 for LF per 100 msec2 (p<0001), 0.5 for HF per 100 msec2 (p=0.001), 0.2 for SDNN per 100 msec (p=0.004), and 0.6 for r-MSSD per 10 msec(p=0.01), respectively). Of these four HRV components, the LF-added model for PAM, HCT-CI, and DRI had the highest values of Δ AIC (16.5, 22.2 and 11.4, respectively). From the analysis with stratification into four LF groups divided equally by the number of transplants (n=28), two-year OS was 92.9, 84.5, 59.7, and 33.2%, respectively (p <0.0001). LF solely represented a better discriminating variable for the prediction of survival. Additionally, from bivariate analysis for OS on each LF-added model to PAM, HCT-CI, or DRI, decreased LF was found to be an independent predictor for lower OS (adjusted HR for LF per 100 msec2: 0.7 (p=0.0003), 0.7 (p<0.0001), or 0.7 (p=0.001), respectively).
Conclusions: Pre-transplant autonomic nervous system dysfunction is a powerful predictor of survival likely because it reflects the comprehensive physiological or pathological status of the patient. Of note, LF was a powerful predictor for survival and statistically independent from well-known prognostic indexes or scoring systems such as PAM, HCT-CI, and DRI.
Disclosures
Nakane: Otsuka: Honoraria. Nakamae:Otsuka: Other: My spouse receives research funding from Otsuka; Kyowa Kirin: Other: My spouse receives research funding from Kyowa Kirin. Nishimoto:Otsuka: Honoraria. Hino:Celgene: Honoraria. Nakamae:Otsuka: Honoraria, Research Funding; Kyowa Kirin: Honoraria, Research Funding.
American Society of Hematology
Title: Pre-Transplant Autonomic Nervous System Malfunction Is a Powerful Predictor for Survival after Allogeneic Hematopoietic Cell Transplantation
Description:
Abstract
Background: Autonomic nerve function can be affected by various factors such as patient activity of daily living, disease status, treatment history and/or comorbidity.
Indeed, autonomic nervous system dysfunction, as indexed by heart rate variability (HRV), has shown prognostic value for various disease outcomes, but its influence on outcomes following allogeneic hematopoietic cell transplantation (allo-HCT) is unclear.
We therefore conducted a prospective observational study to determine the impact of autonomic nervous system dysfunction on outcomes following allo-HCT.
Methods: From July 2011 to July 2013, we prospectively registered patients who had received allo-HCT in our institute.
We also applied well-established examination of HRV as a surrogate maker of the autonomic nervous system.
HRV data were collected from 24-hour ambulatory ECG recordings within 28 days of the starting day of the conditioning regimen for allo-HCT.
Obtained data were analyzed with RR data analysis software (MemCalc/CHIRAM version 3, GMS Co.
, LTD.
, Tokyo, Japan).
The following parameters were employed as markers of HRV: standard deviation of NN interval (SDNN) and the squares of the differences between adjacent normal-to-normal RR intervals (r-MSSD) in time domain analysis, and low-frequency (LF) and high-frequency (HF) power in frequency domain analysis.
Δ Akaike's information criterion (Δ AIC) was used to compare the HRV components-added model to the basic model by the Pre-transplantation Assessment of Mortality (PAM) score, HCT-specific comorbidity index (HCT-CI), or disease risk index (DRI) in a Cox proportional hazards model.
Results: We registered 112 consecutive allo-HCTs (103 patients) who agreed to participate in this study.
The median age of the patients was 45.
5 years (range: 18-66) and the median follow-up period for survivors (76 patients) was 961 days (range: 159-1654).
Diagnoses included acute myeloid leukemia (n=55, 49%), acute lymphoid leukemia/lymphoblastic lymphoma (n=13, 12%), mixed phenotype acute leukemia (n=3, 3%), myelodysplastic syndrome (n=15, 13%), adult T cell leukemia/lymphoma (n=7, 6%), aggressive lymphomas (n=6, 5%), indolent lymphoma/chronic lymphoid leukemia (n=3, 3%), chronic myeloid leukemia/other myeloproliferative neoplasms (n=5, 4%), aplastic anemia (n=2, 2%), and others (n=3, 3%).
Stem cell sources consisted of HLA-matched related donors for 18 transplants (16%), mismatched related donors for 24 transplants (22%), matched unrelated donors for 32 transplants (29%), mismatched unrelated donors for 8 transplants (7%), and cord blood for 30 transplants (27%).
Myeloablative conditioning was employed for 84 transplants (75%).
Median value of LF, HF, SDNN, and r-MSSD was 409 msec2 (range: 27-1279), 103 msec2 (range: 5-1309), 122 msec (range: 48-231), and 20 msec (range: 4-95), respectively.
From univariate analysis, the reduction of LF, HF, SDNN, or r-MSSD was significantly associated with decreased probability of OS (hazard ratio (HR): 0.
7 for LF per 100 msec2 (p<0001), 0.
5 for HF per 100 msec2 (p=0.
001), 0.
2 for SDNN per 100 msec (p=0.
004), and 0.
6 for r-MSSD per 10 msec(p=0.
01), respectively).
Of these four HRV components, the LF-added model for PAM, HCT-CI, and DRI had the highest values of Δ AIC (16.
5, 22.
2 and 11.
4, respectively).
From the analysis with stratification into four LF groups divided equally by the number of transplants (n=28), two-year OS was 92.
9, 84.
5, 59.
7, and 33.
2%, respectively (p <0.
0001).
LF solely represented a better discriminating variable for the prediction of survival.
Additionally, from bivariate analysis for OS on each LF-added model to PAM, HCT-CI, or DRI, decreased LF was found to be an independent predictor for lower OS (adjusted HR for LF per 100 msec2: 0.
7 (p=0.
0003), 0.
7 (p<0.
0001), or 0.
7 (p=0.
001), respectively).
Conclusions: Pre-transplant autonomic nervous system dysfunction is a powerful predictor of survival likely because it reflects the comprehensive physiological or pathological status of the patient.
Of note, LF was a powerful predictor for survival and statistically independent from well-known prognostic indexes or scoring systems such as PAM, HCT-CI, and DRI.
Disclosures
Nakane: Otsuka: Honoraria.
Nakamae:Otsuka: Other: My spouse receives research funding from Otsuka; Kyowa Kirin: Other: My spouse receives research funding from Kyowa Kirin.
Nishimoto:Otsuka: Honoraria.
Hino:Celgene: Honoraria.
Nakamae:Otsuka: Honoraria, Research Funding; Kyowa Kirin: Honoraria, Research Funding.
Related Results
EPD Electronic Pathogen Detection v1
EPD Electronic Pathogen Detection v1
Electronic pathogen detection (EPD) is a non - invasive, rapid, affordable, point- of- care test, for Covid 19 resulting from infection with SARS-CoV-2 virus. EPD scanning techno...
Prognostic Impact of Iron Overload During Follow-up After Allogeneic Stem Cell Transplantation
Prognostic Impact of Iron Overload During Follow-up After Allogeneic Stem Cell Transplantation
Abstract
Abstract 347
Introduction:
Iron overload is frequent in patients undergoing allogeneic hematopoietic ste...
Early Treatment Intensification in High Risk (HR)-AML Patients Using Allogeneic Hematopoietic Stem Cell Transplantion in a Randomized Multicenter Setting.
Early Treatment Intensification in High Risk (HR)-AML Patients Using Allogeneic Hematopoietic Stem Cell Transplantion in a Randomized Multicenter Setting.
Abstract
There are several biological markers that are now known to confer HR in AML patients as there are cytogenetic high risk aberrations, FLT3 length mutations w...
Donor-Derived Unlicensed NK Cells Promote the Hematopoietic Recovery after Allogeneic Hematopoietic Stem Cell Transplantation
Donor-Derived Unlicensed NK Cells Promote the Hematopoietic Recovery after Allogeneic Hematopoietic Stem Cell Transplantation
Introduction
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective therapy for hematopoietic malignancies. Successful engraftment of hema...
The Prognostic Importance of Pre and Post Dendritic Cells in Autologous Transplantation for Diffuse Large B Cell Lymphoma.
The Prognostic Importance of Pre and Post Dendritic Cells in Autologous Transplantation for Diffuse Large B Cell Lymphoma.
Abstract
Pre and post transplant dendritic cell (DC) levels may correlate with survival, GVHD, and relapse in allogeneic BMT. Whether they have prognostic importance...
Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract
Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...
The Impact of Anti-HLA Antibodies on the Prognosis of Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndrome
The Impact of Anti-HLA Antibodies on the Prognosis of Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndrome
Objective To investigate the risk factors of positive anti-HLA antibodies in myelodysplastic syndrome (MDS) patients and gain insights into the impact of anti-HLA antibodies in all...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...

